Comparison of Real-World Treatment Patterns among Psoriasis Patients Prescribed Ixekizumab or Secukinumab

Further Publications Dermatology

Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings

J Am Acad Dermatol

Blauvelt A, Shi N, Somani N, Burge R, Zhu B, Ridenour TL, Lew CR, Zimmerman NM, Atiya B, Murage MJ

doi: 10.1016/j.jaad.2021.06.878

Psoriasis

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

J Eur Acad Dermatol Venereol.

Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K

doi: 10.1111/jdv.16568.

Psoriasis

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

Arch Dermatol Res.

Florek AG, Wang CJ, Armstrong AW

doi: 10.1007/s00403-018-1808-x.

Psoriasis

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Br J Dermatol.

Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K, IXORA-R Study Group

doi: 10.1111/bjd.19509.

Further Publications Dermatology

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

J Eur Acad Dermatol Venereol

da Silva N, Sommer R, Ortmann CE, Jagiello P, Bachhuber T, Augustin M

doi: 10.1111/jdv.17525

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Psoriasis

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T

doi: 10.1111/jdv.16632.

COMMENTED

Psoriasis

Apremilast in psoriasis - a prospective real-world study

J Eur Acad Dermatol Venereol.

Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L

doi: 10.1111/jdv.14598.

Psoriasis

Linkage between patients' characteristics and prescribed systemic treatments for Psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry

J Eur Acad Dermatol Venereol.

Cazzaniga S, Anzengruber F, Augustin M, Boehncke WH, Borradori L, Conrad C, Cozzio A, Djamei V, French LE, Gilliet M, Häusermann P, Heidemeyer K, Itin P, Kolios AGA, Laffitte E, Maul JT, Mainetti C, Naldi L, Navarini AA, Rustenbach SJ, Simon D, Sorbe C, Streit M, Yawalkar N

doi: 10.1111/jdv.15983.

Related content

Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review

A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial

Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: Patient perspective data from the PROSE study

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

Apremilast in psoriasis - a prospective real-world study

Linkage between patients' characteristics and prescribed systemic treatments for Psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry